Clinical study of high-throughput dialysis to improve renal anemia in maintenance hemodialysis patients
高通量透析对维持性血液透析患者肾性贫血改善的临床研究

摘要

目的 探究高通量透析对维持性血液透析患者肾性贫血的改善效果。方法 选择2021年1月~2022年10月间，本院内进行维持性血液透析肾性贫血患者80例作为研究对象。设计对照研究，数字表法将纳入患者分为2组，40例/组。对照组行低通量透析，观察组行高通量透析。比较两组不良反应发生率以及治疗前后贫血指标[血红蛋白（hemoglobin，Hb）、红细胞比容（hematocrit，Hct）、重组人促红细胞生成素（Recombinant human erythropoietin，r-HuEPO）/Hct]、炎性因子[超敏C反应蛋白（hypersensitive C-reactive protein，hs-CRP）、白介素-6（interleukin-6，IL-6）]。结果 不良反应中，观察组肌肉酸痛发生率0.00%，较对照组低（χ2=4.2105；P<0.05）。贫血指标中，观察组治疗后Hb水平为（115.94±15.43）g/L、Hct水平为（29.87±3.43）%，较对照组高（T=6.8813；T=3.9857；P<0.05）；治疗后r-HuEPO/Hct水平为（2.08±0.22）*104 U，较对照组低（T=8.7277；P<0.05）。炎性因子中，观察组治疗后hs-CRP水平为（12.14±2.72）mg/L、IL-6水平为（1.06±0.32）pg/mL，较对照组低（P<0.05）。结论 维持性血液透析肾性贫血治疗中，高通量透析可有效改善患者肾性贫血状态，减轻机体炎症水平，减少肌肉酸痛，值得推广。

Abstract

Objective To explore the improvement effect of high-throughput dialysis on renal anemia in patients with maintenance hemodialysis.
Methods From January 2021 to October 2022, 80 patients with maintenance hemodialysis for renal anemia were selected. Design the controlled study, the digital table method divided the included patients into 2 groups, 40 patients / group. The control group underwent low-throughput dialysis, and the observation group underwent high-throughput dialysis. Comparing the incidence of adverse effects in both groups and the anemia indicators before and after treatment [hemoglobin (hemoglobin, Hb), red BC rit (hematocrit, Hct), recombinant human erythropoietin (Recombinant human erythropoietin, And r-HuEPO) / Hct], inflammatory factor [hypersensitive C-reactive protein (hypersensitive C-reactive protein, hs-CRP), interleukin-6 (interleukin-6, IL-6)].
Results For adverse reactions, the incidence of muscle soreness in the observation group was 0.00%, which was lower than that in the control group (χ2=4.2105; P <0.05). Among the anemia indicators, post posttreatment Hb levels were (115.94 ± 15.43) g / L and Hct levels (29.87 ± 3.43), higher than the control group (T=6.8813; T=3.9857; P <0.05); the r-HuEPO / Hct level was (2.08 ± 0.22) * 104 U and lower than the control group (T=8.7277; P <0.05). Among the inflammatory factors, the hs-CRP levels were (12.14 ± 2.72) mg/L and IL-6 were (1.06 ± 0.32) pg/mL, which were lower than those in the control group (P <0.05).
Conclusion   In the treatment of renal anemia on maintenance hemodialysis, high-throughput dialysis can effectively improve the state of renal anemia, reduce the inflammation level of the body, and reduce muscle pain, which is worth promoting.